Skip to main content
Premium Trial:

Request an Annual Quote

Bruker s Revenues Rise 10 Percent, Earnings Stay Flat in Q1

NEW YORK, May 6 (GenomeWeb News) - Bruker BioSciences yesterday reported a 10-percent increase in revenues and flat earnings for the first quarter of 2005.


Revenues for the quarter were $74.9 million, up from $68.2 million during the first quarter of 2004. Bruker Daltonics, Bruker's mass spectrometry operating business that includes instruments used for proteomics, contributed $42.6 million to total revenues, a 10-percent increase over last year's revenues. $29.8 million of the unit's revenues came from sales of life-science mass spectrometry systems.


Research and development expenses increased to $11 million from $9.9 million during the same quarter last year.


The company's net income fell to $400,000, or $0 per share, from $500,000, or $.01 per share, during the same period a year ago.


As of March 31, Bruker BioSciences had $84.8 million in cash and short-term investments.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.